PAM
SPRB

Panagora Asset Management’s Spruce Biosciences SPRB Stock Holding History

Panagora Asset Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,382
Closed -$199K – 1301
2024
Q1 		$199K Buy
+3,382
New +$860K ﹤0.01% 1160

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Panagora Asset Management's SPRB Position: Q2 2024 in Review

Panagora Asset Management sold out of Spruce Biosciences (SPRB) in Q2 2024, closing a stake of 3,382 shares — an estimated $199K sold.

Panagora Asset Management first reported a position in SPRB in Q1 2024 and held it in 1 quarter. The position peaked at $199K in Q1 2024. 37 funds tracked by Wall St. Rank hold SPRB as of Q2 2024.

  • Panagora Asset Management reported no remaining Spruce Biosciences position as of Q2 2024 after selling out during the quarter.
  • Panagora Asset Management sold 3,382 Spruce Biosciences shares in Q2 2024, an estimated $199K.
  • Panagora Asset Management first reported a position in Spruce Biosciences in Q1 2024 and held it in 1 quarter.
  • Panagora Asset Management's Spruce Biosciences position peaked at $199K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2024.

Based on Panagora Asset Management's 13F filing for Q2 2024, filed 29 Jul 2024.